In longitudinal studies of biomarkers, an outcome of interest is the time at which a biomarker reaches a particular threshold. The CD4 count is a widely used marker of human immunodeficiency virus progression. Because of the inherent variability of this marker, a single CD4 count below a relevant threshold should be interpreted with caution. Several studies have applied persistence criteria, designating the outcome as the time to the occurrence of two consecutive measurements less than the threshold. In this paper, we propose a method to estimate the time to attainment of two consecutive CD4 counts less than a meaningful threshold, which takes into account the patient-specific trajectory and measurement error. An expression for the expected...
Background: Although CD4 cell count monitoring is used to decide when to start antiretroviral therap...
<div><h3>Background</h3><p>Global programs of anti-HIV treatment depend on sustained laboratory capa...
Objective. To compare the prognostic ability of first available measurements of CD4 cell count and v...
Biomarkers play a key role in the monitoring of disease progression. The time taken for an individua...
Assessment of circulating CD4 count change over time in HIV-infected subjects on antiretroviral ther...
Background:CD4(+) cell count is a key measure of HIV disease progression, and the basis of successiv...
In natural history studies of chronic disease, it is of interest to understand the evolution of key ...
The application of biomarkers for ‘recent’ infection in cross-sectional HIV incidence surveillance r...
The application of biomarkers for 'recent' infection in cross-sectional HIV incidence surveillance r...
In studies of the natural history of HIV-1 infection, the time scale of primary interest is the time...
In studies of the natural history of HIV-1 infection, the time scale of primary interest is the time...
BackgroundCD4 cell counts is widely used as a biomarker for treatment progression when studying the ...
Background Although CD4 cell count monitoring is used to decide when to start antiretroviral ther...
CD4+ count is used to assess the clinical status of HIV-infected patients and making informed decisi...
BACKGROUND: Although CD4 cell count monitoring is used to decide when to start antiretroviral therap...
Background: Although CD4 cell count monitoring is used to decide when to start antiretroviral therap...
<div><h3>Background</h3><p>Global programs of anti-HIV treatment depend on sustained laboratory capa...
Objective. To compare the prognostic ability of first available measurements of CD4 cell count and v...
Biomarkers play a key role in the monitoring of disease progression. The time taken for an individua...
Assessment of circulating CD4 count change over time in HIV-infected subjects on antiretroviral ther...
Background:CD4(+) cell count is a key measure of HIV disease progression, and the basis of successiv...
In natural history studies of chronic disease, it is of interest to understand the evolution of key ...
The application of biomarkers for ‘recent’ infection in cross-sectional HIV incidence surveillance r...
The application of biomarkers for 'recent' infection in cross-sectional HIV incidence surveillance r...
In studies of the natural history of HIV-1 infection, the time scale of primary interest is the time...
In studies of the natural history of HIV-1 infection, the time scale of primary interest is the time...
BackgroundCD4 cell counts is widely used as a biomarker for treatment progression when studying the ...
Background Although CD4 cell count monitoring is used to decide when to start antiretroviral ther...
CD4+ count is used to assess the clinical status of HIV-infected patients and making informed decisi...
BACKGROUND: Although CD4 cell count monitoring is used to decide when to start antiretroviral therap...
Background: Although CD4 cell count monitoring is used to decide when to start antiretroviral therap...
<div><h3>Background</h3><p>Global programs of anti-HIV treatment depend on sustained laboratory capa...
Objective. To compare the prognostic ability of first available measurements of CD4 cell count and v...